STOCK TITAN

Mangoceuticals Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Mangoceuticals, Inc. has officially launched its second Mango ED product, which combines its custom compound with Sildenafil, the active ingredient in Viagra. The product is available through the company's telemedicine platform and comes in a Mango-flavored, rapid dissolve tablet. The company aims to leverage the popularity of both Sildenafil and Tadalafil, the active ingredient in Cialis, to drive sales growth. They have also invested in marketing efforts to increase visibility and reach a larger customer base.
Positive
  • Mangoceuticals has launched its second Mango ED product, combining its custom compound with Sildenafil, the active ingredient in Viagra.
  • The product is available through the company's telemedicine platform and comes in a Mango-flavored, rapid dissolve tablet.
  • The company aims to leverage the popularity of both Sildenafil and Tadalafil, the active ingredient in Cialis, to drive strong sales growth.
  • Mangoceuticals has invested in marketing efforts to increase visibility and reach a larger customer base.
Negative
  • None.

Dallas, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” today announced the official commercial launch of its second Mango ED product, which leverages the Company’s existing custom compound alongside Sildenafil, the active ingredient found in Viagra.

Interested consumers can now proceed through the Company’s telemedicine platform and select either a Sildenafil-based Mango or the Company’s original Tadalafil-based Mango ED product, which leverages the active ingredient found in Cialis. Both the Sildenafil and Tadalafil-based Mango ED products are compounded with Oxytocin and L-Arginine in a tasty Mango-flavored, rapid dissolve tablet (RDT) and individually packaged in a master pack of six tablets per package.

“With the launch of our new Sildenafil-based Mango ED product, we can harness the power of the two most popular and successful erectile dysfunction drugs developed over the past two decades and pair them with our own proprietary formulation in a faster-acting, better-tasting ED solution,” remarked Jacob Cohen, CEO and Co-Founder of MangoRx. “Each of these compounds has already cultivated its own sizeable following and both can be effectively integrated into our proprietary blend and delivery mechanism.”

Management notes that Tadalafil and Sildenafil each have their own unique properties, which can lead to different manifest effects among users. For example, Tadalafil has been proven to last longer than Sildenafil due to a half-life more than four times as long. At the same time, Sildenafil may reach full efficacy faster than Tadalafil.

Cohen added, “Perhaps the most important point here is that we are standing on the shoulders of billions of dollars of prior marketing spend. And we have spent the past six months building a huge marketing footprint of our own through our investments in high-traffic, high-relevance podcasts and other highly visible media appearances, interviews, and ads, as well as our own viral marketing and advertising efforts. Now we can pair this visibility with a stable of currently available, market-leading products to drive strong sales growth in the second half of the year.”

About Mango

Created using a special formulation featuring either the same active ingredient as in Cialis (Tadalafil) or Viagra (Sildenafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of either Sildenafil or Tadalafil along with Oxytocin and L-Arginine that have been traditionally used to treat sexual dysfunction.

Mango is a prescription medication that must be approved by a physician. After an individual has completed an online tele-health visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Sildenafil and Tadalafil, one of the main ingredients in Mango, typically have effects that last up to 4 and 36 hours, respectively.

About Mangoceuticals

Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name "Mango" (think: "Man, Go!").

For more information, please visit www.MangoRx.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). These forward-looking statements represent the Company's current expectations or beliefs concerning future events and can generally be identified using statements that include words such as "estimate," "expects," "project," "believe," "anticipate," "intend," "plan," "foresee," "forecast," "likely," "will," "target" or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration ("FDA") and have not had the benefit of the FDA's clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA Act") provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen, has majority voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; the fact that we have a significant number of outstanding warrants to purchase shares of common stock at $1.00 per share, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our Mango ED product, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of high inflation, increasing interest rates and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company's products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company's financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the Quarter ended March 31, 2023. These filings are available at www.sec.gov and at our website at https://investors.mangorx.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial

Or just click here to see why Orange is the new Blue:
https://www.mangorx.com

FOR PUBLIC RELATIONS
Lucky Break Public Relations
MangoRX@luckybreakpr.com
(323) 602-0091 ext. 704

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

MEDIA CONTACT
PHOENIX MGMT Marketing & Consulting
info@phoenix-mediamarketing.com

SOURCE: Mangoceuticals Inc.


FAQ

What is the name of the company launching the new product?

The company launching the new product is Mangoceuticals, Inc.

What is the main ingredient in the new Mango ED product?

The main ingredient in the new Mango ED product is Sildenafil, which is also found in Viagra.

Where can consumers purchase the Mango ED product?

Consumers can purchase the Mango ED product through Mangoceuticals' telemedicine platform.

What flavors are available for the Mango ED product?

The Mango ED product is available in a Mango flavor.

What other active ingredient is combined with Sildenafil in the Mango ED product?

The Mango ED product also contains Oxytocin and L-Arginine.

Mangoceuticals, Inc.

NASDAQ:MGRX

MGRX Rankings

MGRX Latest News

MGRX Stock Data

6.34M
1.74M
37.45%
4.69%
7.69%
Health Information Services
Services-misc Health & Allied Services, Nec
Link
United States of America
DALLAS